Long-term efficacy but rare sustained remission: individual-level 5-year stability in anti-IL5/Rα biologic therapy response for severe asthma

BACKGROUND: For a decade, anti-interleukin-5/receptor α (IL5/Rα) has been available to treat severe asthma, with marked reductions in exacerbation rates and maintenance oral corticosteroid burden. However, little is known about long-term, real-world sustained remission. We aimed to assess the stability of response to anti-IL5/Rα over 5 years. METHODS: ) >80% predicted, Asthma Control Questionnaire score <1.5 and no switch to non-anti-IL5/Rα) was assessed annually for 5 years. RESULTS: and persistent uncontrolled symptoms. 5-year sustained freedom from exacerbations and maintenance oral corticosteroid use was seen in 33.6% of patients. CONCLUSIONS: Patients with severe asthma respond well to anti-IL5/Rα, with substantial improvements across all domains over 5 years. Remission is a dynamic state with intermittent relapses, and sustained long-term remission is rare using current domains.